Back to top
more

Gilead Sciences, Inc. (GILD)

(Delayed Data from NSDQ)

$70.92 USD

70.92
4,281,727

+0.43 (0.61%)

Updated Nov 13, 2018 03:58 PM ET

Add to portfolio

1-Strong Buy 1        

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1
2
3
4
5
S&P
Strong Buy
Buy
Hold
Sell
Strong Sell
500
25.68%
18.56%
10.1%
5.5%
2.33%
10.82%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

B Value | F Growth | F Momentum | F VGM

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

View All Zacks #1 Ranked Stocks

Trades from $1

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Zacks News

Zacks Equity Research

Amarin's Vascepa Cuts Heart Risk in Outcomes Test, Stock Down

Amarin (AMRN) posts detailed data from a late-stage cardiovascular outcomes study on its fish oil drug Vascepa. The stock takes a hit.

GHDX GILD AMRN ALXN

Zacks Equity Research

Cronos (CRON) to Report Q3 Earnings: What's in the Offing?

Cronos' (CRON) third-quarter results are likely benefit from the company's collaboration initiatives to become one of the most promising cannabis company.

BMY GILD TLRY CRON

Zacks Equity Research

Tilray (TLRY) to Report Q3 Earnings: What's in the Cards?

We expect investors to focus on Tilray's (TLRY) pipeline updates when it reports third-quarter results.

BMY NVS GILD TLRY

Zacks Equity Research

Medicines Company (MDCO) Q3 Loss Widens, Inclisiran in Focus

The Medicines Company (MDCO) suffers a wider-than-expected loss in Q3. At the same time, the company posts negative revenues.

GILD ALNY ALXN MDCO

Zacks Equity Research

Endo (ENDP) Stock Declines Despite Q3 Earnings & Revenue Beat

Endo (ENDP) tops revenues and earnings expectations in the third quarter and raises its annual view. However, the results from the cellulite treatment trial are disappointing.

MRK BMY GILD ENDP

Zacks Equity Research

Arena Pharmaceuticals (ARNA) Beats on Q3 Earnings and Sales

Arena Pharmaceuticals (ARNA) betters loss estimates in Q3. Also, the top line surpasses the consensus mark.

ARNA GILD ALXN SBPH

Zacks Equity Research

Aerie (AERI) Q3 Earnings Miss, Rhopressa Gains Traction

Aerie's (AERI) Q3 loss is wider than expected on account of higher expenses. Nevertheless, Rhopressa's sales beat estimates as demand picks up.

PFE GILD AERI BHC

Zacks Equity Research

PDL BioPharma (PDLI) Q3 Earnings Top, Revenues Rise, Stock Up

PDL BioPharma's (PDLI) earnings trump estimates in Q3. Higher royalties and product sales aid a significant surge in year-over-year revenues.

ALXN PDLI BIIB GILD

Zacks Equity Research

Prothena (PRTA) Reports Narrower-Than-Expected Loss in Q3

Prothena (PRTA) posts narrower-than-expected loss in the third quarter. With the failure of lead drug, NEOD001, the focus is now on its mid-stage candidate, prasinezumab.

RHHBY CELG PRTA GILD

Zacks Equity Research

Pacira (PCRX) Q3 Earnings and Revenues Surpass Estimates

Pacira Pharmaceuticals (PCRX) encourages with better-than-expected earnings and revenues in Q3

JNJ ALXN GILD PCRX

Zacks Equity Research

Puma Biotech (PBYI) Q3 Loss Narrows, Nerlynx Pulls Stock Down

Puma Biotech (PBYI) betters loss estimates in Q3. However, its only marketed drug, Nerlynx, disappoints with low sequential growth and as a result, shares take a hit.

RHHBY ALXN GILD PBYI

Zacks Equity Research

Radius Health (RDUS) Posts Narrower-Than-Expected Q3 Loss

Radius Health (RDUS) posts narrower Q3 loss as Tymlos sales gains traction.

LLY GILD AMGN RDUS

Zacks Equity Research

Agios (AGIO) Q3 Earnings Beat, Tibsovo Sales Drive Stock

Agios' (AGIO) loss tops estimates in Q3. Its precision medicine Tibsovo's performance in the very first quarter after approval in July leads to a significant year-over-year revenue growth.

AGIO CELG GILD CLBS

Zacks Equity Research

Emergent (EBS) Q3 Earnings and Revenues Fall Shy of Estimates

Emergent (EBS) disappoints with weaker-than-expected results in the third quarter of 2018.

SNY GSK GILD EBS

Zacks Equity Research

Conatus' (CNAT) Q3 Loss In Line, Revenues Lag Estimates

Conatus (CNAT) incurs in-line loss for the third quarter of 2018. Sales miss estimates.

NVS PFE CNAT GILD

Zacks Equity Research

bluebird (BLUE) Q3 Loss Narrower Than Expected, Revenues Beat

bluebird (BLUE) incurs narrower-than-expected Q3 loss on account of higher collaboration revenues. The pipeline progress looks encouraging.

CELG REGN GILD BLUE

Zacks Equity Research

Biotech ETFs in Focus on String of Q3 Earnings Beat

Biotech ETFs draw attention post impressive Q3 results.

BBH IBB FBT ALXN AMGN BIIB GILD

Zacks Equity Research

Acorda (ACOR) Q3 Earnings Top Estimates, Ampyra Sales View Up

Acorda's (ACOR) Q3 rides high on earnings and revenue beat amid a strong generic competition for its MS drug Ampyra and the expected launch of its Parkinson's candidate, Inbrija.

CLBS ACOR GILD MYL

Zacks Equity Research

The Zacks Analyst Blog Highlights: Gilead Sciences, Amgen, Vertex Pharmaceuticals, Celgene and Regeneron Pharmaceuticals

The Zacks Analyst Blog Highlights: Gilead Sciences, Amgen, Vertex Pharmaceuticals, Celgene and Regeneron Pharmaceuticals

CELG REGN VRTX AMGN GILD

Zacks Equity Research

Intercept (ICPT) Gains on Earnings and Revenue Beat in Q3

Intercept's (ICPT) revenues beat estimates, owing to strong Ocaliva sales in the third quarter of 2018.

ICPT GILD GLMD MDGL

Zacks Equity Research

Biotech Stock Roundup: Celgene, Amgen, Vertex Impress in Q3, DRNA Soars on LLY Deal

Impressive third-quarter results by most biotech bigwigs were the key highlights of the week. Most companies upped their guidance.

GILD CELG REGN RARE ALXN AMGN DRNA VRTX

Zacks Equity Research

Aduro (ADRO) Q3 Loss Narrower Than Expected, Revenues Lag

Aduro's loss (ADRO) betters estimates in Q3. However, lower license and collaboration fees induce a dip in year-over-year revenues.

JNJ NVS GILD ADRO

John Blank

Can the Strong Economy Save the Stock Market?

The U.S. economy is the MOST important fundamental.

RHHBY GILD BMY

Zacks Equity Research

Gilead Sciences (GILD) Gains As Market Dips: What You Should Know

In the latest trading session, Gilead Sciences (GILD) closed at $70.90, marking a +1.66% move from the previous day.

GILD

Zacks Equity Research

Dr. Reddy's (RDY) Earnings and Revenues Improve Y/Y in Q2

Dr. Reddy's (RDY) surpasses earnings and revenue estimates on strength across segments in the second quarter of fiscal 2019.

GILD GNMSF RDY CRSP